• Home
  1. Home
  2. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Scientific article
OA Policy
English

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

Contributors

Renner, Christoph; Zinzani, Pier Luigi; Gressin, Rémy; Klingbiel, Dirk; Dietrich, Pierre-Yves; Hitz, Felicitas; Bargetzi, Mario; Mingrone, Walter; Martinelli, Giovanni; Trojan, Andreas; Bouabdallah, Krimo; Lohri, Andreas; Gyan, Emmanuel; Biaggi, Christine; Cogliatti, Sergio; Bertoni, Francesco; Ghielmini, Michele; Brauchli, Peter; Ketterer, Nicolas

Published in

Haematologica, vol. 97, no. 7, p. 1085-1091

Publication date

2012

Abstract

Mantle cell lymphoma accounts for 6% of all B-cell lymphomas and is generally incurable. It is characterized by the translocation t(11;14) leading to cyclin D1 over-expression. Cyclin D1 is downstream of the mammalian target of rapamycin threonine kinase and can be effectively blocked by mammalian target of rapamycin inhibitors. We set out to examine the single agent activity of the orally available mammalian target of rapamycin inhibitor everolimus in a prospective, multicenter trial in patients with relapsed or refractory mantle cell lymphoma (NCT00516412).

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Humans
  • Lymphoma, Mantle-Cell/drug therapy/mortality
  • Male
  • Middle Aged
  • Neoplasm Proteins/antagonists & inhibitors
  • Neoplasm Staging
  • Prospective Studies
  • Protein Kinase Inhibitors/administration & dosage/adverse effects
  • Recurrence
  • Remission Induction
  • Sirolimus/administration & dosage/adverse effects/analogs & derivatives
  • TOR Serine-Threonine Kinases/antagonists & inhibitors

UNIGE affiliation entities

UNIGE research groups

Citation (ISO format)

RENNER, Christoph et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. In: Haematologica, 2012, vol. 97, n° 7, p. 1085–1091. doi: 10.3324/haematol.2011.053173

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0390-6078
655views
507downloads

Technical informations

Creation

16/12/2014 07:30:00

First validation

16/12/2014 07:30:00

Update

14/03/2023 22:28:21

Status update

14/03/2023 22:28:20

Last indexation

30/10/2024 21:31:28
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated